Freeline Therapeutics(FRLN) - 2023 Q2 - Earnings Call Transcript

Naomi Aoki - Investor Relations Paul Schneider - CFO and Director Operator Naomi Aoki Before we begin, I would like to remind everyone that we will be making forward-looking statements. which may include our plans and expectations with respect to our research and development pipeline, clinical trials and financial projections, all of which involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from those statements. A description of ...